The pharmacological properties of the novel selective 5-HT3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat.
The purpose of this study was to investigate the pharmacological properties of the novel, selective 5-HT3 receptor antagonist, alosetron, and its effects on transit time in both the normal and perturbed small intestine of the rat. Alosetron concentration-dependently inhibited radioligand binding in membranes containing rat and human 5-HT3 receptors with estimated pKi values of 9.8 (n = 3) and 9.4 (n = 6), respectively. In selectivity studies alosetron had little or no significant affinity for any of the many other receptors and ion channels studied. Alosetron potently antagonized the depolarization produced by 5-HT in the rat vagus nerve (estimated pKB value of 9.8, n = 25). In anaesthetized rats, i. v. administration of alosetron inhibited 2-methyl-5-HT induced bradycardia (Bezold Jarisch index) at 1 and 3 microg kg-1, with an agonist dose ratio of approximately 3.0 at 1.0 microg kg-1, = 3-5). Alosetron administered via the duodenum also inhibited this reflex, with duration of action that was significantly longer than that seen with ondansetron (120-60 min, respectively, n = 6). Alosetron had no significant effect on normal small intestinal propulsion in the rat, but fully reversed the increase in intestinal propulsion (96%, n = 3) produced by egg albumin challenge. Alosetron is a highly selective 5-HT3 antagonist which normalizes perturbed small intestinal propulsion. Previous clinical data in IBS patients together with the transit data provide a good rationale for further studies with alosetron in IBS patients.
Clayton
N M
NM
GlaxoWellcome, Stevenage, Herts., UK. nc0537@ggr.co.uk
Sargent
R
R
Butler
A
A
Gale
J
J
Maxwell
M P
MP
Hunt
A A
AA
Barrett
V J
VJ
Cambridge
D
D
Bountra
C
C
Humphrey
P P
PP
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000818:Animals; D002243:Carbolines / Q000627:therapeutic use*; D003000:Clonidine / Q000031:analogs & derivatives / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D005215:Fasting; D005772:Gastrointestinal Transit / Q000187:drug effects*; D007421:Intestine, Small / Q000187:drug effects*; D017294:Ondansetron / Q000494:pharmacology; D010047:Ovalbumin / Q000494:pharmacology; D011869:Radioligand Assay; D051381:Rats; D012016:Reference Values; D012018:Reflex / Q000187:drug effects; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D014630:Vagus Nerve / Q000187:drug effects
D000316:Adrenergic alpha-Agonists; D002243:Carbolines; D012702:Serotonin Antagonists; C090840:alosetron; D017294:Ondansetron; C016986:apraclonidine; D010047:Ovalbumin; D003000:Clonidine